

CLAIMS

1. A process for preparing a compound of formula (I):



(I)


comprising transforming a compound of formula (IV):



(IV),


or a salt thereof, to the compound of formula (I).

2. The process of claim 1, wherein transforming the compound of formula (IV) to the compound of formula (I) comprises preparing a compound of formula (VI):



(VI)


optionally wherein preparing the compound of formula (VI) comprises contacting the compound of formula (IV) or a compound of formula (VII):



(VII)

with quinine, optionally wherein the compound of formula (VII) is obtained by contacting the compound of formula (IV) with (R)-α-methylbenzylamine.

3. The process of claim 1, wherein transforming the compound of formula (IV) to the compound of formula (I) comprises preparing a compound of formula (VII):




(VII)

optionally wherein the compound of formula (VII) is obtained by contacting the compound of formula (IV) with (R)-α-methylbenzylamine.


4. The process of any one of claims 1 to 3, wherein transforming a compound of formula (IV) to the compound of formula (I) comprises

(a) contacting the compound of formula (IV), the compound of formula (VI), or the compound of formula (VII) with a compound of formula (V):



(V)

to afford a compound of formula (III):




, and

(III)

optionally transforming the compound of formula (III) to the compound of formula (I); or


(b) transforming the compound of formula (IV), the compound of formula (VI), or the compound of formula (VII) to a compound of formula (VIII):



, and


(VIII)

optionally contacting the compound of formula (VIII) with a compound of formula (V):



(V)

to afford a compound of formula (III):




, and

(III)

optionally transforming the compound of formula (III) to the compound of formula (I).


5. The process of any one of claims 1 to 4, further comprising recrystallizing the compound of formula (I) from a suitable solvent to afford crystalline Form A of the compound of formula (I).

6. A process for preparing a compound of formula (II):



(II)

comprising transforming a compound of formula (VII):




(VII)

to the compound of formula (II).


7. The process of claim 6, wherein transforming the compound of formula (VII) to the compound of formula (II) comprises

(a) contacting the compound of formula (VII) with a compound of formula (XXI):



(XXI)

to afford a compound of formula (XX):




, and

(XX)


optionally transforming the compound of formula (XX) to the compound of formula (II), optionally wherein transforming the compound of formula (XX) to the compound of formula (II) comprises treating the compound of formula (XX) with ammonia to afford the compound of formula (II); or

(b) transforming the compound of formula (VII) to a compound of formula (VIII):



(VIII)


8. The process of claim 6 or 7, further comprising transforming a compound of formula (IV):



(IV)

to the compound of formula (VII), optionally wherein transforming the compound of formula (IV) to the compound of formula (VII) comprises contacting the compound of formula (IV) with (R)-α-methylbenzylamine.


9. The process of any one of claims 1 to 5 and 8, further comprising transforming a compound of formula (IX):



(IX)

to the compound of formula (IV);

optionally further comprising transforming a compound of formula (X):




(X)

to the compound of formula (IX),

wherein:


R^1 is –C(O)-Z, –C(O)OZ, –C(O)CH=CH-Z, or –P(O)Z_2; and

Z is selected from C_6-C_{10} aryl optionally substituted with CN, halo, NO_2, C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkyl, and/or C_1-C_4 haloalkoxy; C_1-C_4 alkyl; and C_1-C_4 haloalkyl, optionally wherein the compound of formula (X) has formula (X'):




(X')

optionally further comprising transforming a compound of formula (XI):




(XI)

to the compound of formula (X), wherein the compound of formula (XI) has formula (XI'):



(XI')


optionally further comprising transforming a compound of formula (XII):



(XII)

to the compound of formula (XI);


optionally further comprising transforming a compound of formula (XIII):



(XIII)


to the compound of formula (XII);

optionally further comprising contacting a compound of formula (XIV):



(XIV)


with a compound of formula (XV):




(XV)

to afford the compound of formula (XIII).


10. A compound of formula:




(III) ,




(IV) ,




(V) ,




(VI),




(VII),




(VIII),




(IX),




(X),




(X’),




(X’’),




(X-A),




(X’-A),




(X’’-A),




(X-B),




(X’-B),




(X’’-B),





(XI),





(XI’),



(XI'')



(XII)



(XIII)



(XVI)



(XVI-A)



(XVI-B)



(XVII)



(XVIII)



(XIX)



(XX)



(XXI)



(XXII)



(XXIII)



(XXIV)


(XXV)


(XXVI)


(XXVII)


(XXVIII)



(XXIX)


wherein:

R^1 is –C(O)-Z, –C(O)OZ, –C(O)CH=CH-Z, or –P(O)Z_2;


Z is selected from C_6-C_{10} aryl optionally substituted with CN, halo, NO_2, C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkyl, and/or C_1-C_4 haloalkoxy; C_1-C_4 alkyl; and C_1-C_4 haloalkyl; and

R^2 is C_1-C_6 alkyl;


optionally wherein the compound has formula:




(III)




(VI)




(IX)




(X-A)




(X'-A)




(X''-A)




(X-B)




(X'-B)




(X''-B)




(XI),




(XI'),




(XI'')




(XII),




(XIII),




(XVI-A)




(XVI-B)




(XVII),




(XVIII),




(XIX),




(XXII),




(XXIII),




(XXIV),




(XXV),




(XXVI),



(XXVII),




(XXVIII), or



(XXIX).


11. A compound of formula (I):



(I)

wherein the compound is in a crystalline solid form.

12. A pharmaceutical composition comprising a compound of formula (I):



(I)

and one or more pharmaceutically acceptable carriers or vehicles, wherein the compound of formula (I) is in a crystalline solid form.

13. The pharmaceutical composition of claim 12, wherein at least 85% of the compound of formula (I) present in the pharmaceutical composition is in a crystalline solid form.

14. The compound of claim 11, or the pharmaceutical composition of claim 12 or 13, wherein the crystalline solid form is Form A, optionally wherein Form A is characterized by:

an X-ray powder diffraction pattern (XRPD) pattern comprising at least one approximate peak position (degrees 2-theta $\pm$ 0.2) when measured using Cu K_α radiation, selected from 9.0, 11.4, 13.4, 13.7, 13.8, 14.6, 15.3, 17.0, 17.2, 18.9, 20.1, 23.9, 24.5, 24.8, 26.3, 28.0, 28.1, 28.3, 30.7, and 32.1; or an X-ray powder diffraction pattern (XRPD) pattern comprising at least one approximate peak position (degrees 2-theta $\pm$ 0.2) when measured using Cu K_α radiation, selected from 13.4, 17.2, and 18.9; or an X-ray powder diffraction pattern (XRPD) pattern comprisingat least one approximate peak position (degrees 2-theta $\pm$ 0.2) when measured using Cu K_α radiation, selected from 13.4, 17.2, and 18.9; and at least one approximate peak position (degrees 2-theta $\pm$ 0.2) when measured using Cu K_α radiation, selected from 9.0, 11.4, and 20.1; or an X-ray powder diffraction pattern (XRPD)

pattern comprising at least one approximate peak position (degrees 2-theta ± 0.2) when measured using Cu K_α radiation, selected from 13.4, 17.2, and 18.9; at least one approximate peak position (degrees 2-theta ± 0.2) when measured using Cu K_α radiation, selected from 9.0, 11.4, and 20.1; and at least one approximate peak position (degrees 2-theta ± 0.2) when measured using Cu K_α radiation, selected from 13.7, 13.8, and 24.8; and/or

a solid state ^{19}F NMR spectrum having at least one peak at a chemical shift selected from -74.5, -139.5, and -161.5 ppm; and/or

a solid state ^{13}C NMR spectrum having at least one peak at a chemical shift selected from 169.8, 157.7, 151.3, 146.1, 142.8, 141.0, 135.3, 134.8, 126.4, 123.9, 122.6, 108.9, 85.1, 79.8, 70.2, 67.3, 59.3, 48.4, 44.0, 25.1, and 11.6 ppm; and/or

an orthorhombic crystal system, a $P2_12_12_1$ space group, and a unit cell having dimensions measured at 100(2) K on an x-ray diffractometer equipped with Cu Kα radiation (λ=1.54178 Å) of:


a=7.0(1) Å α=90°

b=8.3(1) Å; β=90°

c=38.8(1) Å γ=90°.

15. A pharmaceutical composition comprising:

45-55 wt % of a solid dispersion comprising a polymer and a compound of formula (II):



(II) ;

42-50 wt % of microcrystalline cellulose;

2-4 wt % of croscarmellose sodium; and

0.5-1.5 wt % of magnesium stearate.

16. The pharmaceutical composition of claim 15, wherein the pharmaceutical composition is a tablet core composition, optionally wherein the tablet core composition is coated with a tablet coating, optionally wherein the

pharmaceutical composition comprises about 50 mg of the compound of formula (II), optionally wherein the pharmaceutical composition comprises an intragranular blend and extragranular blend.